Graph Pipeline

SM-88 is a first-in-class combination therapy in Phase II development for pancreatic and prostate cancer.

SM-88 has shown complete and partial responses across 15 different cancer types, including some of the most common and hard to treat cancer types, such as pancreatic, prostate, breast, lung, glioma, ovarian, Ewing’s sarcoma, sarcoma and colon cancer.

Patented formulations include the combination of SM-88’s dysfunctional tyrosine derivative with other therapeutic classes intended to specifically destabilize the cancer cells. The modified D/L racemic tyrosine is the core component of Tyme’s SM-88 therapy and is believed to disrupt protein synthesis in the cancer cells, and ultimately lead to apoptosis.